Xiaoxiang Chen

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Mitochondrial Dna

Neoadjuvant Chemotherapy

Top Venues

Journal of ovarian research

Cancer management and research

Drug design, development and therapy

Reproductive sciences (Thousand Oaks, Calif.)

This page only lists publications with an associated author ORCID identifier.

Publications

Xinyi Hong, Shanhu Qiu, Xia Wu, Sizhen Chen, Xiaoxiang Chen, Bei Zhang, Aiqin He, Yun Xu, Jianqing Wang, Yingchun Gao, Xizhong Xu, Li Sun, Yang Zhang, Libing Xiang, Jundong Zhou, Qun Guan, Yanling Zhu, Haiyan Liu, Hao Xu, Ying Zhou, Bing-Wei Chen, Yang Shen
Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study. Drug design, development and therapy 17 (2023)
Qian Zhao, Jing Ni, Jiayin Dong, Xianzhong Cheng, Li Xiao, Qi Xue, Xia Xu, Wenwen Guo, Xiaoxiang Chen
Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report. Reproductive sciences (Thousand Oaks, Calif.) (2022)
Jing Ni, Xianzhong Cheng, Qian Zhao, Zhiqin Dai, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Yan Wang, Xiaoxiang Chen
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. Journal of ovarian research 14 (1) (2021)
Jing Ni, Yan Wang, Xianzhong Cheng, Fang Teng, Congyang Wang, Suping Han, Xiaoxiang Chen, Wenwen Guo
Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer. Cancer management and research 12 (2020)
Hongyuan Gu, Rui Zhou, Jing Ni, Xia Xu, Xianzhong Cheng, Yan Li, Xiaoxiang Chen
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial. Journal of ovarian research 13 (1) (2020)
Jing Ni, Xianzhong Cheng, Rui Zhou, Xia Xu, Wenwen Guo, Xiaoxiang Chen
Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. Journal of ovarian research 12 (1) (2019)